- Home
- BCAB vs GDTC Comparison
BCAB vs GDTC Comparison
Compare BCAB & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCAB | GDTC |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 12.4M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BCAB | GDTC |
|---|---|---|
| Price | $0.18 | $1.04 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 17.5K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.19 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $300,000.00 | N/A |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.73 |
| 52 Week High | $1.43 | $3.68 |
Technical Indicators
Market Signals| Indicator | BCAB | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 49.75 |
| Support Level | $0.14 | $0.96 |
| Resistance Level | $0.27 | $1.25 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 19.32 | 83.82 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.